Clinical Trial Update: Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents [NA]

View source ↗

Summary

Clinical trial assessing whether MMP2 and MMP9 biomarker levels predict outcomes for patients with metastatic renal cell carcinoma treated with anti-angiogenic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Snippet

Sponsor: Institut Paoli-Calmettes | Conditions: Kidney Cancer | NA | Status: ACTIVE_NOT_RECRUITING